MDR General Provisions compliance binder showing regulatory framework scope applicability and compliance requirements sections beside a laptop displaying EU MDR regulatory framework with general provisions requirements compliance and guidance tabs illustrating EU MDR 2017/745 articles 1 and 2 analysis

EU MDR 2017/745 Articles 1 and 2 Explained 2026

by
with no comment
Insights
Insights: EU Medical Device Regulation
EU MDR 2017/745: Articles 1 and 2 Explained 2026
Regulation (EU) 2017/745 entered into force in May 2017 and became fully applicable in May 2021. By September 2026, 33,175 applications have been submitted to EU Notified Bodies, but only 17,549 MDR certificates have been issued. The gap is structural. This analysis examines what Articles 1 and 2 of EU MDR 2017/745 actually establish, why the scope and definitions have generated compliance challenges that persist years into implementation, and what the evidence means for manufacturers, authorised representatives, and quality leaders navigating the transition.
15,626 Applications without MDR certificates across 51 EU Notified Bodies

Source: EC 18th Notified Bodies Survey, March 2026

13-18 Months average per MDR certification review at EU Notified Bodies

Source: MedTech Europe survey / MedTech Dive

123 Articles and 17 Annexes in EU MDR 2017/745; Articles 1 and 2 determine if all others apply

Source: EUR-Lex: Regulation (EU) 2017/745

Insight Summary

1
As of October 2025, 15,626 MDR applications remain uncertified across 51 EU Notified Bodies. At 13 to 18 months per review, this backlog cannot be cleared before December 2027 transition deadlines for the highest-risk device classes.
2
Article 1 of EU MDR expanded scope beyond the previous MDD in three significant ways: Annex XVI products without a medical purpose now fall under the full MDR framework, Software as a Medical Device is formalised under a uniform EU classification pathway, and accessories now require independent conformity assessment.
3
Article 2 introduced 71 regulatory definitions. The definition of “manufacturer” now extends to any organisation that reprocesses a single-use device or substantially modifies a device already placed on the market. Obligations that historically belonged only to the original equipment manufacturer now apply to hospitals, repackagers, and downstream distributors who modify devices.
4
The European Commission’s December 2025 Staff Working Document (SWD(2025) 1050) acknowledged systemic implementation failures: Notified Body capacity bottlenecks, high compliance costs for SMEs, duplicated reporting obligations, and uneven uptake of the EUDAMED digital infrastructure.
5
More than half of MDD-certified manufacturers reported portfolio reductions as a direct result of MDR implementation, with low-volume, niche, and legacy products at the highest risk of permanent withdrawal from the EU market.
Key Insight
Articles 1 and 2 of EU MDR are not administrative introductions. They are compliance triggers. Misreading scope determines whether your product requires Notified Body involvement at all. Misreading definitions determines who bears manufacturer liability. Both errors are recurring and structurally costly.
The most consequential early-stage compliance error is classifying a product outside MDR scope when it falls within it, or failing to recognise when an organisation’s activities make it a “manufacturer” under Article 2’s expanded definition. The Notified Body backlog makes these errors more damaging: late recognition means late application, and late application means late certification in a system already running years behind deadline.

What the Data Shows

DATA
The European Commission’s 18th Notified Bodies Survey (published March 2026, data through October 2025) shows 33,175 MDR applications submitted but only 17,549 certificates issued, a net gap of 15,626 applications across 51 active Notified Bodies. Certificates grew 18% from the prior survey snapshot, but the rate of issuance remains insufficient to close the gap before transition deadlines. Source: EC 18th Notified Bodies Survey, March 2026
INTERPRETATION
An 18% growth rate in certificates sounds promising. It is not, in context. At 13 to 18 months per review, the 15,626-application backlog represents at minimum 2 to 3 more years of processing at current Notified Body capacity. This means the December 2027 deadline for Class III and certain Class IIb implantables is arithmetically out of reach for manufacturers who have not already been in active review.
WHY IT MATTERS
For compliance leaders, this is not an abstract system-level problem. It is a direct business risk: manufacturers without a valid MDR certificate by their applicable transition deadline cannot legally place the device on the EU market. The scale of the gap involves thousands of products across all device classes.
DATA
As of April 2022, MedTech Europe survey data covering an estimated 60 to 70% of the EU device market by revenue showed that over half of manufacturers reported portfolio reductions as a direct result of MDR implementation. Out of 25,034 devices on MDD certificates at that time, more than 11,000 had either been removed from the market or were already transitioning. Source: PA Consulting / MedTech Europe data
INTERPRETATION
More than half of manufacturers restructuring their EU portfolios confirms that MDR’s scope change, encoded in Articles 1 and 2, is not merely administrative. The cost of compliance for some product lines, especially low-volume niche and legacy devices, exceeds the commercial return of maintaining EU market access. The regulation is actively reshaping which devices remain available in Europe.
WHY IT MATTERS
The EU Commission’s 2025 Economic Operator Survey explicitly flags patient access risks from portfolio withdrawals, particularly for specialised and rare-condition devices where no alternative exists. This is the patient-safety consequence that Articles 1 and 2 scope decisions are now producing at scale.
DATA
The European Commission’s December 2025 Staff Working Document (SWD(2025) 1050) identified four systemic implementation failures in MDR: Notified Body capacity bottlenecks, high compliance costs particularly for SMEs, duplicated reporting obligations (especially PSUR frequency), and uneven uptake of EUDAMED digital tools. Source: EC SWD(2025) 1050, December 2025
INTERPRETATION
The Commission’s own working document is a significant admission. It acknowledges that the regulatory architecture established in 2017 has generated structural friction that was not fully anticipated. The identification of PSUR frequency as ‘disproportionate for stable technologies’ suggests further amendment activity is likely, continuing the pattern of Regulations 2023/607 and 2024/1860.
WHY IT MATTERS
For compliance leaders, this means the regulatory framework for MDR is not stable. The obligations established in the base regulation are being amended, and will likely continue to be amended, faster than many compliance programmes can absorb. Monitoring the EU Commission’s MDCG guidance and amendment regulations is now a standing compliance function, not a one-time implementation activity.

Article 1: Scope - Broader Than Its Predecessor in Three Significant Ways

The compliance challenges the data reveals are traceable to specific structural decisions made in Articles 1 and 2 of EU MDR 2017/745. Understanding why these provisions generate so much complexity requires reading what they actually say.

Annex XVI products without a medical purpose

Article 1(2) brings specific product groups without an intended medical purpose under the full MDR framework. Annex XVI lists the categories: coloured contact lenses, high-intensity electromagnetic radiation equipment for skin or body treatment, liposuction equipment, invasive laser equipment for non-medical purposes, and others. These products were previously outside any EU medical device regulation. They now require conformity assessment, technical documentation, clinical evaluation, and in many cases Notified Body involvement. Source: EU MDR Article 1(2), Annex XVI

Software as a Medical Device formalised

Article 1 and the accompanying definition in Article 2 formally incorporate Software as a Medical Device (SaMD) into the MDR framework. Under the previous MDD, software classification was handled inconsistently across member states. EU MDR, combined with MDCG 2019-11 guidance on software qualification and classification, creates a unified classification pathway that brings a substantial number of standalone software products into regulatory scope for the first time. For manufacturers of health apps, clinical decision support software, and AI-assisted diagnostic tools, Article 1 scope is the first compliance determination they must make. Source: MDCG 2019-11; EU MDR Article 2(1)

Accessories treated as devices in their own right

Under the MDD, accessories were regulated but with limited specificity. EU MDR Article 1 and the Article 2 definition of ‘accessory for a medical device’ clarifies that accessories are subject to the same conformity assessment requirements as the devices they complement, independently, not automatically via the parent device’s certification. This affects manufacturers whose products are positioned as accessories: they must demonstrate independent compliance rather than relying on the parent device’s CE marking. Source: EU MDR Article 2(2)

Regulation, not Directive: direct enforceability in all member states

A structural shift that is not apparent from the article numbers but is significant for compliance: MDR is a Regulation, not a Directive. The MDD required each EU member state to transpose the requirements into national law, creating variation in implementation. EU MDR 2017/745 is directly enforceable in all member states without transposition, creating uniform legal obligations that cannot be softened or varied at national level. Compliance strategies built around member-state-specific flexibility under the MDD require reassessment. Source: EUR-Lex: EU MDR legal structure

Article 2: 71 Definitions - Three That Generate the Most Compliance Risk

“Manufacturer” now includes reprocessors and substantial modifiers

Article 2(30) defines “manufacturer” to include any natural or legal person who reprocesses a single-use device for reuse within the EU, or who assembles, packages, processes, repackages, labels, or assigns a purpose to a device in a way that modifies it sufficiently to affect compliance with the original CE marking. This definition pulls healthcare institutions that reprocess single-use devices directly into the manufacturer’s regulatory obligations. They are not simply using a certified device. They are manufacturing one, with all associated technical documentation, QMS, and vigilance reporting obligations. Source: EU MDR Article 2(30), Article 17

“Intended purpose” now governed by labelling and marketing, not manufacturer intent alone

Article 2(12) defines “intended purpose” as the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use, or in promotional or sales materials. The practical consequence is that a device’s regulatory status can be altered by how it is marketed, not only by how it is engineered. A software product described in promotional material as supporting clinical diagnosis may fall into MDR scope even if the manufacturer intended it as a general-purpose analytics tool. Regulatory affairs oversight of marketing and promotional content is a compliance function, not merely a sales function. Source: EU MDR Article 2(12)

“Placing on the market” extends to digital distribution channels

Article 2(28) defines “placing on the market” to include making a device available in the EU for distribution, consumption, or use, including via websites, app stores, and other digital channels directed at EU users. A SaMD developer who distributes a health application through an app store accessible to EU users is placing a device on the EU market under this definition, even if the company has no EU legal entity and no EU distributor. This has significant implications for non-EU manufacturers who have not previously considered themselves subject to EU regulatory requirements. The obligation to appoint an Authorised Representative under Article 11 follows directly from this definition. Source: EU MDR Articles 2(28), 11

Six Compliance Areas Triggered by Articles 1 and 2

📋

Scope Determination

Article 1 scope analysis must be documented at the product level before any other compliance work begins. Undocumented scope determinations are not a compliance position.

🏭

Manufacturer Status

Article 2(30) manufacturer definition analysis must cover all organisations that reprocess, repackage, relabel, or substantially modify CE-marked devices.

💻

Software Classification

MDCG 2019-11 software qualification and classification guidance applies to any software product that may fall within EU MDR scope under Article 1 and Article 2(1).

📣

Marketing Review

Article 2(12) intended purpose definition makes promotional materials a classification risk factor. Regulatory affairs must review all external communications for scope-triggering language.

🌍

Non-EU Manufacturer Obligations

Article 2(28) placing on market definition means non-EU manufacturers distributing via digital channels to EU users are in scope and must appoint an Authorised Representative under Article 11.

📅

Transition Deadline Mapping

December 2027 and December 2028 transition deadlines require backwards planning from Notified Body expected review completion dates, not from the deadline date itself.

What This Means for Compliance Leaders

The scope question must be answered before the QMS question

Many compliance programmes begin with ISO 13485 and quality system preparation. Under EU MDR, the foundational question is whether Article 1 scope applies to the product and whether Article 2 definitions make the organisation a manufacturer, importer, distributor, or authorised representative. Getting the scope analysis wrong means either under-investing in compliance or over-investing. Both errors carry commercial consequences.

The Notified Body timeline must drive the programme plan, not the deadline date

Given 13 to 18 months per review and a 15,626-application backlog, waiting for deadline proximity to trigger Notified Body engagement is not a viable risk management strategy. The data implies that manufacturers who are not currently in active review for devices requiring certification by December 2027 may not receive certificates in time even if they submit applications today. Programme planning must begin from the Notified Body’s expected review completion date, working backwards.

Marketing and labelling are compliance documents, not sales materials

The Article 2(12) definition of intended purpose makes promotional and marketing content a determinant of regulatory classification. Regulatory affairs must review and approve marketing claims, app store descriptions, website language, and sales materials for any product that is in or near MDR scope, not as a legal review of advertising, but as a classification decision that determines whether a Notified Body is required and what clinical evidence is needed.

Healthcare institutions reprocessing single-use devices are manufacturers under MDR

Hospitals and healthcare institutions that reprocess single-use devices for repeated use are subject to Article 17 of EU MDR and, through the Article 2(30) manufacturer definition, are expected to comply with manufacturer obligations, subject to specific derogations in Article 17(2) for health institutions. Compliance programmes must address technical documentation, clinical evaluation, and vigilance reporting, not just procurement and sterilisation procedures.

10 Important EU MDR 2017/745 Facts for Compliance Leaders

Ten data points from EU Commission surveys, MedTech Europe research, and the EU MDR text that compliance and regulatory leaders need to know.

33,175 Total MDR applications submitted (Oct 2025)

33,175 applications submitted to EU Notified Bodies through October 2025. Only 17,549 MDR certificates issued, a gap of 15,626 applications. Certificate volume grew 18% from the prior snapshot.

51 Active EU Notified Bodies for MDR

51 Notified Bodies designated for EU MDR as of the 18th survey. Notified Body capacity, not regulatory complexity, is the primary constraint on certification throughput.

71 Article 2 regulatory definitions

Article 2 of EU MDR introduces 71 regulatory definitions. Three generate the most compliance risk: manufacturer (including reprocessors), intended purpose (governed by labelling and marketing), and placing on the market (including digital channels).

50%+ Manufacturers reporting portfolio reductions

More than half of MDD-certified manufacturers reported portfolio reductions as a direct result of MDR implementation. Low-volume, niche, and legacy products face the highest risk of permanent EU market withdrawal.

Dec 2027 Class III and Class IIb implantable deadline

December 31, 2027 is the transition deadline for Class III devices and certain Class IIb implantables under Regulation 2024/1860. Devices without a valid MDR certificate by this date cannot be legally placed on the EU market.

13-18mo Average Notified Body review time

Applications submitted today realistically complete review in mid-to-late 2027 at the earliest. For December 2027 deadlines, there is virtually no margin for incomplete submissions or additional information requests.

4 Systemic failures in EU MDR acknowledged by EC

The European Commission’s December 2025 Staff Working Document identified four systemic MDR implementation failures: Notified Body capacity, SME costs, duplicated reporting, and EUDAMED uptake.

Dec 2028 All remaining Class IIb, IIa, Im/Is/Ir deadline

December 31, 2028 is the final transition deadline for all remaining Class IIb, Class IIa, and Class Im/Is/Ir devices as amended by Regulation 2024/1860.

May 2021 MDR full application date

Regulation (EU) 2017/745 entered into force May 2017 and became fully applicable May 26, 2021, following a one-year COVID-19 extension from the original May 2020 date.

ARTICLES 1 AND 2
= ALL SUBSEQUENT MDR OBLIGATIONS FLOW FROM THESE TWO Scope and Definitions Are Not Administrative Introductions

Article 1 determines whether the regulation applies to a given product at all. Article 2 determines who bears manufacturer liability. Every subsequent obligation in EU MDR’s 123 articles and 17 annexes applies only to the extent that Articles 1 and 2 establish scope and role. Getting either wrong is not a procedural error: it is a foundational compliance failure. Source: Regulation (EU) 2017/745, EUR-Lex

5 Myths About EU MDR 2017/745 Articles 1 and 2

Myth 1

If a product has no medical purpose, it cannot be in EU MDR scope.

Article 1(2) and Annex XVI of EU MDR explicitly bring products without a medical purpose into the full MDR regulatory framework. Coloured contact lenses, high-intensity aesthetic laser equipment, liposuction equipment, and other aesthetic devices listed in Annex XVI now require conformity assessment, clinical evaluation, and in most cases Notified Body involvement, the same pathway as a Class IIa or IIb medical device. The absence of a medical purpose is no longer a basis for exclusion from EU MDR. Source: EU MDR Article 1(2), Annex XVI

Myth 2

A hospital that reprocesses a single-use device is just a user, not a manufacturer.

Under Article 2(30) and Article 17 of EU MDR, a health institution that reprocesses a single-use device for reuse within the institution is subject to manufacturer-equivalent obligations. Article 17(2) provides specific derogations: health institutions reprocessing for internal use are not required to appoint an Authorised Representative or apply CE marking, but they must comply with equivalent standards for quality management, technical documentation, clinical evaluation, and device traceability. The legal position of ‘just a user’ no longer applies to any institution reprocessing single-use devices. Source: EU MDR Article 2(30), Article 17

Myth 3

The intended purpose of a software product is determined by its technical design, not its marketing.

Article 2(12) of EU MDR defines intended purpose based on what the manufacturer’s labelling, instructions for use, promotional materials, and sales materials state. A software product that is engineered as a general analytics platform but described in app store listings or marketing materials as supporting clinical diagnosis is in EU MDR scope based on the marketing language, regardless of the technical design. Regulatory affairs review of all external communications is a classification risk management activity under EU MDR, not merely a legal review of advertising. Source: EU MDR Article 2(12)

Myth 4

A non-EU manufacturer distributing a health app through an app store is not placing a device on the EU market.

Article 2(28) of EU MDR defines placing on the market to include making a device available to users in the EU through any channel, including digital distribution platforms such as app stores directed at EU users. A non-EU company with no EU legal entity and no EU distributor that makes a health application downloadable by EU users is placing a device on the EU market under this definition. The obligation to appoint an Authorised Representative under Article 11 applies as a consequence. The digital delivery mechanism does not create an exemption from EU MDR scope. Source: EU MDR Articles 2(28), 11

Myth 5

Once a compliance programme is built to EU MDR 2017/745, it can be maintained without active monitoring of new guidance.

The EU Commission’s December 2025 Staff Working Document acknowledged systemic implementation failures and identified areas likely to be subject to further regulatory reform, including PSUR frequency and EUDAMED obligations. The MDCG guidance library has been updated continuously since 2021, with MDCG 2021-24 revised in April 2026 and MDCG 2025-10 on post-market surveillance published in 2025. Each MDCG publication can affect classification, clinical evaluation, UDI, or PSUR obligations without amending the base regulation. A compliance function not tracking MDCG publications is working from an incomplete version of EU MDR requirements even if it is current on the regulation text. Source: EC SWD(2025) 1050

Impact on Medical Device Manufacturers and Compliance Teams

⏰

Certification Timeline Risk Is Acute for December 2027 Devices

With 15,626 applications pending and 13 to 18 month review times, manufacturers without an active Notified Body review for December 2027 deadline devices are at significant risk of missing the transition date. The arithmetic of the current backlog does not support a scenario where late submissions can be processed in time. This risk requires escalation to board level, not management of it within the regulatory affairs function.

📉

Portfolio Reduction Is a Direct Financial Consequence of Scope Decisions

More than half of manufacturers have reduced their EU device portfolios as a result of MDR implementation. The portfolio decisions that determine which products to pursue through MDR certification and which to withdraw from the EU market are fundamentally scope and classification decisions under Articles 1 and 2. Undocumented or incorrect scope analyses at the product level are directly generating market withdrawal decisions that reduce revenue and patient access.

💻

Software and Digital Health Products Face a New Regulatory Reality

AI-assisted diagnostic tools, clinical decision support software, and health applications that previously operated outside EU medical device regulation are now in scope under Article 1 and MDCG 2019-11. For software companies that have not previously operated in a regulated environment, the Article 2 definitions create manufacturer obligations including technical documentation, post-market surveillance, and vigilance reporting that require building new compliance infrastructure from scratch.

🏥

Healthcare Institutions Face Manufacturer Obligations They Did Not Previously Have

Hospitals and healthcare institutions that reprocess single-use devices are now subject to manufacturer-equivalent obligations under Article 2(30) and Article 17. Many institutions have compliance programmes built around purchasing and using CE-marked devices. These programmes do not cover the technical documentation, clinical evaluation, and traceability obligations that apply to reprocessing. A compliance gap assessment specifically against Article 17 obligations is required for any institution that reprocesses single-use devices.

Practical Implications: What the Evidence Requires

📋

Document Article 1 Scope for Every Product

Every product in or near MDR scope requires a written scope determination signed off by regulatory affairs. Undocumented scope determinations are not a compliance position. For borderline products, the MDCG Manual on Borderline and Classification (updated April 2026) is the authoritative reference.

🏭

Apply Article 2 Manufacturer Analysis to All Downstream Organisations

Any organisation that repackages, relabels, reprocesses, or substantially modifies a CE-marked device must assess whether those activities trigger manufacturer status under Article 2(30). Legal counsel and regulatory affairs must assess this jointly for distributors, hospitals, and downstream entities.

📣

Integrate Regulatory Affairs into Marketing Review

Article 2(12) intended purpose definition means all external communications, including app store descriptions, website product pages, and sales presentations, are classification-risk documents. Regulatory affairs sign-off on marketing content for in-scope products is not optional under EU MDR.

⏰

Contact Notified Body This Quarter for December 2027 Devices

If any product requiring certification by December 2027 does not yet have a signed application with a Notified Body, the timeline risk is acute. Submission today targets mid-to-late 2027 at the earliest. Engage a designated Notified Body this quarter, not this year.

📰

Build MDCG Guidance Monitoring into the Compliance Calendar

MDCG guidance is updated continuously. MDCG 2021-24 was revised April 2026. MDCG 2025-10 was published 2025. Each update can affect classification, clinical evaluation, or PMS obligations without amending the base regulation. Monitoring is a standing compliance function.

🔄

Plan for Continuing Regulatory Change

The EC December 2025 SWD signals PSUR frequency and EUDAMED obligations are candidates for reform. Compliance programmes should be designed to absorb regulatory changes, not built as static implementations of the 2017 text.

Executive Takeaway

Three Things Compliance and Regulatory Leaders Should Act On Now
1
If any product requiring Notified Body certification by December 2027 does not yet have a signed application with a Notified Body, the timeline risk is acute. The 13 to 18 month review window means submission today targets mid-to-late 2027 at earliest. Contact a designated Notified Body this quarter, not this year.
2
Article 1 and Article 2 scope and definition reviews should be documented at the product level. A verbal agreement that ‘this is not a device’ or ‘we are a distributor, not a manufacturer’ is not a compliance record. Documented determinations with regulatory affairs sign-off are the starting point of every subsequent compliance decision.
3
The EC December 2025 Staff Working Document signals continuing regulatory change. PSUR frequency, EUDAMED obligations, and Notified Body reporting requirements are all areas the Commission identified as candidates for reform. Compliance programmes should be built to absorb changes, not to implement a fixed 2017 text as if it were static law.

Frequently Asked Questions

What does EU MDR 2017/745 Article 1 actually cover?

Article 1 of Regulation (EU) 2017/745 defines the subject matter and scope of the regulation. It establishes that MDR applies to medical devices and accessories for medical devices, software qualifying as a medical device, and certain products without a medical purpose listed in Annex XVI. It also clarifies interactions with other EU legislation. Understanding Article 1 is the prerequisite for every downstream compliance decision under MDR.

What types of products are in MDR scope that were not under the MDD?

Three main categories: (1) Annex XVI products without a medical purpose, including coloured contact lenses, high-intensity aesthetic equipment, liposuction equipment, and invasive aesthetic laser devices; (2) Software as a Medical Device formalised under a uniform EU framework rather than member-state discretion; and (3) accessories for devices now requiring independent conformity assessment rather than relying on the parent device’s certification. Devices reclassified into higher risk classes under MDR’s more detailed Annex VIII classification rules also now require Notified Body involvement they previously did not.

When does a hospital or healthcare institution become a manufacturer under EU MDR?

Under Article 2(30) and Article 17 of EU MDR, a health institution becomes subject to manufacturer-equivalent obligations when it reprocesses a single-use device for reuse within the institution. Article 17(2) provides specific derogations for health institutions reprocessing within the institution’s own use: they are not required to appoint an Authorised Representative or apply for CE marking, but must comply with equivalent standards for quality management, technical documentation, and device traceability. Source: EU MDR Article 17

How does EU MDR define intended purpose and why does it matter for classification?

Article 2(12) defines intended purpose based on what the manufacturer’s labelling, IFU, promotional materials, and sales materials state, not the manufacturer’s internal engineering intent. A product described in marketing as assisting clinical diagnosis is in MDR scope regardless of how the engineering team characterises it internally. This definition means classification is a function of what is communicated publicly. Regulatory affairs review of all external communications is a classification risk management activity. Source: EU MDR Article 2(12)

What are the current MDR transition deadlines?

As amended by Regulation (EU) 2023/607 and Regulation (EU) 2024/1860: Class III custom-made devices, May 26, 2026; Class III devices and Class IIb implantables (excluding sutures, staples, dental fillings, braces, tooth crowns, and screws, wedges, plates, wires, pins, clips, and connectors), December 31, 2027; all other Class IIb, Class IIa, Class Im/Is/Ir devices, December 31, 2028. Legacy devices must meet specific conditions including a valid QMS and active Notified Body engagement.

What does the Notified Body capacity gap mean for a manufacturer applying for certification today?

The 18th Notified Bodies Survey (March 2026) shows 15,626 applications pending across 51 active Notified Bodies, with average review times of 13 to 18 months. A manufacturer submitting a complete application today faces a realistic certification window of mid-to-late 2027 at the earliest. For devices with December 2027 deadlines, this leaves virtually no margin for incomplete submissions or requests for additional information. The practical implication is that applications should already be submitted and complete. Source: EC 18th Notified Bodies Survey

Where can manufacturers find the official EU MDR text and MDCG guidance?

The official text of Regulation (EU) 2017/745 is published on EUR-Lex. All MDCG guidance documents are published by the European Commission at health.ec.europa.eu. The EUDAMED database is at eudamed.ec.europa.eu. The NANDO database lists all designated EU Notified Bodies and their scope of designation.

Sources

Government and Regulatory Sources

  • Regulation (EU) 2017/745 of the European Parliament and of the Council on medical devices (EUR-Lex): primary legislative text. Articles 1 (scope), 2 (definitions including manufacturer, intended purpose, placing on market), 11 (authorised representative), 17 (reprocessing single-use devices), and Annex XVI (products without medical purpose) cited throughout.
  • European Commission SWD(2025) 1050 final, December 2025: Commission Staff Working Document identifying four systemic MDR implementation failures: Notified Body capacity bottlenecks, SME compliance costs, duplicated reporting obligations (PSUR frequency), and uneven EUDAMED uptake.
  • European Commission: MDR/IVDR Implementation, MDCG Guidance and Notified Bodies Surveys: source for EC 18th Notified Bodies Survey (published March 2026, data through October 2025), 33,175 applications and 17,549 certificates issued.
  • Regulation (EU) 2023/607 and Regulation (EU) 2024/1860: amending regulations extending MDR/IVDR transitional provisions and establishing December 2027 and December 2028 transition deadlines.

Research and Industry Sources

  • MedDeviceGuide: EU MDR Notified Body Capacity Crisis 2026-2027 (May 2026): analysis of EC 18th Notified Bodies Survey data; 33,175 applications, 17,549 certificates, 15,626 gap; 18% certificate growth; 13 to 18 month review timeline.
  • MedTech Dive: Notified Bodies Have Not Yet Issued MDR Certificates for 85% of Legacy Devices (2022): MedTech Europe survey data covering 60 to 70% of EU market by revenue; 30% of smaller businesses without access to MDR-designated Notified Bodies; 13 to 18 month certification timeline.
  • PA Consulting: We’re Heading Toward a Bottleneck for EU MDR Approvals (2024): MedTech Europe portfolio reduction data; over half of manufacturers reporting portfolio reductions; 25,034 MDD-certificate devices in April 2022.
  • Pure Global: EU Commission 2025 Economic Operator Survey on Medical Device Availability: survey findings on certification delays, niche device withdrawal risks, and supply continuity concerns for specialised and rare-condition devices.

Related VelSafe Articles

Insights

VelSafe Insights: Regulatory and Compliance Analysis

Evidence-led analysis of regulatory trends, enforcement patterns, and compliance implications across healthcare, safety, and regulated industry sectors.

Insights

FDA 483 Enforcement Statistics: Trends and What They Mean

FDA 483 citation data analysis covering enforcement patterns, most-cited observations, and what the inspection record shows for regulated manufacturers.

Insights

FDA Jurisdictions and Enforcement Data: Insights

FDA jurisdiction scope, enforcement actions by jurisdiction, inspection trends, and what the enforcement record means for regulated manufacturers and importers.

EU MDR Compliance Insight Library
Navigating EU MDR 2017/745?
Explore VelSafe’s regulatory compliance insight library for evidence-based analysis of EU MDR scope, transition deadlines, Notified Body strategy, and MDCG guidance updates.
Explore All Insights

VelSafe Staff is the editorial team at VelSafe.com, a workplace safety and compliance content platform. Our team of safety professionals, regulatory specialists, and compliance writers produces guides, tips, and insights on OSHA regulations, pharmaceutical GMP, healthcare compliance, and occupational health across construction, manufacturing, oil and gas, and life sciences sectors..

Comments are closed.